@DavidAdrwJones

DPhil student @Oxford_NDPH.

Joined August 2019
  • Tweets50
  • Following91
  • Followers22
1Media
Out this week, this new publication explores how the distribution of trial site locations, may lead to disparities in patient representation in clinical trials. bit.ly/416VENC @DavidJCutter @LymphomaAction @bloodcancer_uk @NATCAN_news @WileyGlobal @NHSEngland @HQIP
2
4
155
Fascinating - the hospital at which a patient with Hodgkin lymphoma is treated in England has more effect on the variation in radiotherapy usage than sex of the patient. Suggests standardisation of approach is not yet achieved! #ISHL13 #lymsm. @DavidJCutter @DavidAdrwJones
1
2
8
1,762
1/5 Great to see a the first published analysis of the NHS Galleri Trial at the ESMO conference last week in Madrid and the role of NHS DigiTrials in recruiting across a range of ages, socioeconomic and ethnic groups. Success in some areas yet more to do in others.
2
9
2
16
4,603
The (many) problems with a new study criticizing cancer screening Ty ⁦@statnews⁩ for providing me space to explain why the question the authors asked is important and why their answer is unsupportable, and likely incorrect. statnews.com/2023/09/07/canc…

What a viral study criticizing cancer screening gets very, very wrong

A new study says that most cancer screening doesn’t save lives. But proving that kind of negative isn’t just hard — it’s impossible.

statnews.com
29
2
58
16,755
There’s a lot of discussion as to how to manage the cancer backlogs. In this paper we present a model for regional allocation to use all available capacity in the NHS. Can be used across cancer types thelancet.com/journals/lanep…

Managing the cancer backlog: a national population-based study of patient mobility, waiting times...

Spare surgical capacity potentially exists in the present configuration of hospitals providing cancer surgery and requires regional allocation for efficient utilisation.

thelancet.com
2
24
1,716
🚨new job alert🚨 looking for a #postdoc with interests in quants to model choices with our team at @HERC_Oxford further details/apply at tinyurl.com/bdwxr5cb #HealthEconomics
8
1
15
3,930
Pertinent issue across the oncology space! Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers ja.ma/3ljrZ1q via @JAMAOnc part of @JAMANetwork
2
28
For my radiotherapy friends: Ionising radiation and cardiovascular disease: systematic review and meta-analysis bmj.com/content/380/bmj-2022…

Ionising radiation and cardiovascular disease: systematic review and meta-analysis

Objective To systematically review and perform a meta-analysis of radiation associated risks of cardiovascular disease in all groups exposed to radiation with individual radiation dose estimates....

bmj.com
1
3
179
Exploring the effect of researcher choices on statistical results: 73 teams estimate the same effect size with the same data, and generate 1,253 different results. As always, statistical results depend on modeling decisions. pnas.org/doi/10.1073/pnas.22…

Observing many researchers using the same data and hypothesis reveals a hidden universe of uncert...

This study explores how researchers’ analytical choices affect the reliability of scientific findings. Most discussions of reliability problems in ...

pnas.org
5
27
1
101
17,583
Should we be using #ProtonBeamTherapy (PBT) for consolidation in Hodgkin lymphoma?☢️ Firstly we need to translate dosimetry differences into morbidity and mortality. AND look at value over photon-RT. A🧵on our new paper. @GeorgeNtentas @DavidJCutter @becshakir @PaoloCandio
Economics of Population Health Research Centre@EPH_Oxford23 Jan 2023
NEW PUBLICATION Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma @DavidAdrwJones @PaoloCandio #healtheconomics sciencedirect.com/science/ar…
1
4
2
5
2,462
more replies
So PBT unlikely❌to be cost-effective for intermed-stage HL in the UK... With the all important caveats: 👉 Model full of unquantifiable uncertainties (how much certainty can we give our estimate of breast cancer incident 30 years from now?)
1
66
👉 Should PBT costing approaches include sunk costs? Is this inflating our estimates? 👉 Natural history of disease model used UK data, results not generalisable to other juristictions.
53
Load more